申请人:Eisinger Magdalena
公开号:US08501791B2
公开(公告)日:2013-08-06
The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II diabetes, Syndrome X, diabetic retinopathy, spinal cord injury, nerve injury, acute neurodegenerative disorders, chronic neurodegenerative disorders, plexopathies, male erectile dysfunction, dry eyes, acne, dry skin, aged skin, seborrheic dermatitis, rosacea, excessive ear wax, meibomian gland disorder, pseudofolliculitis, yeast infections, dandruff, hidradenitis suppurativa, ocular rosacea and eccrine gland disorder.
本发明涉及一种新型的1,2,4-噻二唑-2-ium衍生物,可用作黑色素皮质素受体的激动剂或拮抗剂。更具体地说,本发明的化合物可用于治疗代谢、中枢神经系统和皮肤疾病,如肥胖症、口服葡萄糖耐量受损、血糖升高、2型糖尿病、X综合症、糖尿病视网膜病变、脊髓损伤、神经损伤、急性神经退行性疾病、慢性神经退行性疾病、神经丛病、男性勃起功能障碍、干眼症、痤疮、干燥皮肤、老化皮肤、脂溢性皮炎、酒渣鼻、过度耳垢、美波腺障碍、假毛囊炎、酵母感染、头皮屑、汗腺炎、眼部酒渣鼻和汗腺障碍。